All Stories

  1. Combined Tribenoside/Lidocaine Rectal Cream (Procto-Glyvenol®) Promotes Tissue Repair in a Preclinical Model of Acute Complicated Anal Fissure
  2. Global, regional, and national burden of breast cancer among females, 1990–2023, with forecasts to 2050: a systematic analysis for the Global Burden of Disease Study 2023
  3. The Mediterranean diet: historical benefits and contemporary challenges in Southern Italy
  4. ATTENUATION COEFFICIENT MEASUREMENT IN SCREENING FOR METABOLIC DYSFUNCTION-ASSOCIATED STEATOTIC LIVER DISEASE: BETWEEN DIAGNOSTIC ACCURACY AND ECONOMIC REALITY
  5. Different association of gBRCA1 and gBRCA2 variants with HER2-low status in invasive breast cancer: findings from a Ukrainian study
  6. Accuracy of attenuation coefficient measurement (ACM) for hepatic steatosis: comparison with MRI proton density fat fraction (MRI-PDFF) and chemical fat analysis using multimodal liver fat phantoms
  7. Accuracy of the hepatorenal index with additional standardized acoustic depth assessment for steatotic liver disease diagnosis
  8. Biological and Therapeutic Potentials of MXenes in Tumor Microenvironment-Driven Oncology
  9. Global, regional, and national burden of chronic kidney disease in adults, 1990–2023, and its attributable risk factors: a systematic analysis for the Global Burden of Disease Study 2023
  10. Dapagliflozin in the Strategy of Secondary Prevention of Ischaemic Heart Disease: Clinical Results in Patients with Post-Myocardial Infarction Cardiosclerosis
  11. Systemic Modulation of Inflammation and Vascular Remodelling in a Stable Post-Infarction Cohort under the Influence of Losartan
  12. Editorial: Fecal Microbiota Transplants: challenges in translating microbiome research to clinical applications
  13. Burden of 375 diseases and injuries, risk-attributable burden of 88 risk factors, and healthy life expectancy in 204 countries and territories, including 660 subnational locations, 1990–2023: a systematic analysis for the Global Burden of Disease Study...
  14. Global burden of 292 causes of death in 204 countries and territories and 660 subnational locations, 1990–2023: a systematic analysis for the Global Burden of Disease Study 2023
  15. Global age-sex-specific all-cause mortality and life expectancy estimates for 204 countries and territories and 660 subnational locations, 1950–2023: a demographic analysis for the Global Burden of Disease Study 2023
  16. Efficacy of probiotic co-supplementation with omega-3 PUFAs on pancreatic beta-cell function in type 2 diabetes
  17. Efficacy of Losartan within a Multicomponent Secondary Prevention Strategy for Cardiovascular Events in Post-Ischemic Stroke Patients
  18. Integration of dapagliflozin into a multicomponent therapeutic strategy of secondary prevention in patients with type 2 diabetes mellitus after myocardial infarction
  19. GBD 2023 Cardiovascular Disease Collaborators
  20. Relationship between leukocyte telomere length and early markers of kidney damage in people with type 2 diabetes
  21. Association of leukocyte telomere length and HbA1c with post-COVID-19 syndrome in type 2 diabetes: a cross-sectional pilot study
  22. Genetic alterations affect immune contexture of non-small cell lung cancer: Ukrainian study
  23. Genomics of Type 1 Diabetes in Ukraine Initiative
  24. Features of correction of vitamin D deficiency in patients with diabetic kidney disease: the role of vitamin D-binding protein
  25. Early markers of renal damage in type 2 diabetes: role of vitamin D-binding protein
  26. Inter- and Intraobserver variability of attenuation coefficient measurement in innovative ultrasound diagnosis of metabolic dysfunction-associated steatotic liver disease: a cross-sectional study
  27. Defining the high-risk category of patients with cutaneous melanoma: a practical tool based on prognostic modeling
  28. Immune cells in thyroid adenoma and carcinoma: uncovering a hidden value of assessing tumor-host interplay and its potential application in thyroid cytopathology
  29. The impact of war on people with type 2 diabetes in Ukraine: a survey study
  30. Unveiling risk factors for post-COVID-19 syndrome development in people with type 2 diabetes
  31. HbA1c and leukocyte mtDNA levels as major factors associated with post-COVID-19 syndrome in type 2 diabetes patients
  32. Gut Microbiota, Deranged Immunity, and Hepatocellular Carcinoma
  33. Early diagnosis of mineral and bone disorders in patients with diabetic kidney disease on the background of type 2 diabetes
  34. Corrigendum to: ’Protective effect of vaginal resveratrol administration on joint tissues in ovariectomized rats: Targeting mTOR and сaspase 3’ [Biomed. Pharmacother. (2023) 115176/165]
  35. Gender Differences in Patients with Prolactinoma: Single-center Ukrainian Experience
  36. Association between intestinal microflora and obesity
  37. Digital pathology implementation in cancer diagnostics: towards informed decision-making
  38. Microbiota substances modulate dendritic cells activity: A critical view
  39. Probiotic co-supplementation with absorbent smectite for pancreatic beta-cell function in type 2 diabetes: a secondary-data analysis of a randomized double-blind controlled trials
  40. Prognostic factors for surgical treatment of prolactin-secreting pituitary adenomas
  41. Assessment of renal and cardiovascular risks in patients with type 2 diabetes when using non-steroidal mineralocorticoid receptor antagonists
  42. Accuracy Assessment of Attenuation Coefficient Measurement For Ultrasound Hepatic Steatometry by Comparing Multimodal Performance Findings with Mri-Pdff And Chemical Analysis of Fat Content
  43. Predicting BRAF Mutations in Cutaneous Melanoma Patients Using Neural Network Analysis
  44. Ethical navigation of biobanking establishment in Ukraine: learning from the experience of developing countries
  45. Accuracy of attenuation coefficient measurement (ACM) for real-time ultrasound hepatic steatometry: Comparison of simulator/phantom data with magnetic resonance imaging proton density fat fraction (MRI-PDFF)
  46. Probiotic for Pancreatic β-Cell Function in Type 2 Diabetes: A Randomized, Double-Blinded, Placebo-Controlled Clinical Trial
  47. Probiotics for pancreatic β-cell function: from possible mechanism of action to assessment of effectiveness
  48. Protective effect of vaginal resveratrol administration on joint tissues in ovariectomized rats: Targeting mTOR and сaspase 3
  49. Antimicrobial activity of dietary supplements based on bacterial lysate of Lactobacillus rhamnosus DV
  50. The detrimental consequences of two consecutive disasters impacting cytopathology in Ukraine: COVID followed by the war
  51. Incidence of BRAF Mutations in Cutaneous Melanoma: Histopathological and Molecular Analysis of a Ukrainian Population
  52. Gut microbiota in patients with COVID-19 and type 2 diabetes: A culture-based method
  53. Efficacy of interferon alpha for the treatment of hospitalized patients with COVID-19: A meta-analysis
  54. Efficacy and safety of fecal microbiota transplantation via colonoscopy as add-on therapy in patients with mild-to-moderate ulcerative colitis: A randomized clinical trial
  55. Fecal Microbiota Transplantation in Diseases Not Associated with Clostridium difficile: Current Status and Future Therapeutic Option
  56. Microbiome and Obesity
  57. Triglyceride Lowering with Pemafibrate to Reduce Cardiovascular Risk
  58. Changes in Metabolic Parameters in Patients with Diabetic Kidney Disease Depending on the Status of D3
  59. Fecal microbiota transplantation in patients with post-infectious irritable bowel syndrome: A randomized, clinical trial
  60. Resveratrol Effects on the Reproductive System in Ovariectomized Rats: Deciphering Possible Mechanisms
  61. Nutrition program, physical activity and gut microbiota modulation: a randomized controlled trial to promote a healthy lifestyle in students with vitamin D3 deficiency
  62. Precision oncology: ethical challenges and justification
  63. Akkermansia muciniphila as a novel powerful bacterial player in the treatment of metabolic disorders
  64. Response to neoadjuvant chemotherapy in breast cancer: do microRNAs matter?
  65. Immune Microenvironment of Muscular-Invasive Urothelial Carcinoma: The Link to Tumor Immune Cycle and Prognosis
  66. Global multi-stakeholder endorsement of the MAFLD definition
  67. Effect of a specific Escherichia coli Nissle 1917 strain on minimal/mild hepatic encephalopathy treatment
  68. Correction of Androgen Deficiency in Men with Type 2 Diabetes
  69. Current Status and Future Therapeutic Options for Fecal Microbiota Transplantation
  70. Gut Microbiota Interactions With Obesity
  71. SEMI-QUANTITATIVE EVALUATION OF THE HEPATIC AND PANCREATIC STEATOSIS BY GRAY SCALE ECHOGENICITY
  72. STRATIFICATION OF LIVER STEATOSIS BY THE ATTENUATION COEFFICIENT MEASUREMENT (ACM) OF THE HAND-HELD ULTRASOUND DEVICE
  73. Probiotics and obesity associated disease: an extended view beyond traditional strains
  74. Cardiovascular and Renal Outcomes with Efpeglenatide in Type 2 Diabetes
  75. Изменения состава микробиоты кишечника, связанные с ожирением: новые результаты метагеномного анализа
  76. Оценка клинической эффективности заместительной терапии препаратом Декап у пациентов с сахарным диабетом типа 2 и сопутствующей неалкогольной жировой болезнью печени при дефиците витамина D
  77. Histological differentiation impacts the tumor immune microenvironment in gastric carcinoma: Relation to the immune cycle
  78. Alleviation of halitosis by use of probiotics and their protective mechanisms in the oral cavity
  79. Immunomodulatory role of Faecalibacterium prausnitzii in obesity and metabolic disorders
  80. Microbial and immune markers of patients with metabolic syndrome and cardiovascular diseases: perspectives for early diagnostics
  81. Vitamin D in the prevention and treatment of type-2 diabetes and associated diseases: a critical view during COVID-19 time
  82. Metabolic Benefits of Probiotic Combination with Absorbent Smectite in type 2 Diabetes Patients a Randomised Controlled Trial
  83. Probiotic Composition and Chondroitin Sulfate Regulate TLR-2/4-Mediated NF-κB Inflammatory Pathway and Cartilage Metabolism in Experimental Osteoarthritis
  84. Effect of linagliptin versus placebo on cardiovascular and kidney outcomes in nephrotic-range proteinuria and type 2 diabetes: the CARMELINA randomized controlled trial
  85. Next generation of strain specific probiotics in diabetes treatment: the case of Prevotella copri
  86. Hepatic steatosis indices as predictors of vitamin D3 deficiency in patients with NAFLD associated with type 2 diabetes
  87. Dietary pattern, colonic microbiota and immunometabolism interaction: new frontiers for diabetes mellitus and related disorders
  88. Probiotic and omega-3 polyunsaturated fatty acids supplementation reduces insulin resistance, improves glycemia and obesity parameters in individuals with type 2 diabetes: A randomised controlled trial
  89. Vitamin D3 deficiency is associated with more severe insulin resistance and metformin use in patients with type 2 diabetes
  90. Probiotics function and modulation of the immune system in allergic diseases
  91. Mechanisms of the Impact of Hashimoto Thyroiditis on Papillary Thyroid Carcinoma Progression: Relationship with the Tumor Immune Microenvironment
  92. Combined effects of probiotic and chondroprotector during osteoarthritis in rats
  93. Effects of Linagliptin on Cardiovascular and Kidney Outcomes in People With Normal and Reduced Kidney Function: Secondary Analysis of the CARMELINA Randomized Trial
  94. Crosstalk between gut microbiota and osteoarthritis: A critical view
  95. Cardiovascular and kidney outcomes of linagliptin treatment in older people with type 2 diabetes and established cardiovascular disease and/or kidney disease: A prespecified subgroup analysis of the randomized, placebo‐controlled CARMELINA® trial
  96. New insights on strain-specific impacts of probiotics on insulin resistance: evidence from animal study
  97. Importance of the Microbiota Inhibitory Mechanism on the Warburg Effect in Colorectal Cancer Cells
  98. Probiotics and smectite absorbent gel formulation reduce liver stiffness, transaminase and cytokine levels in NAFLD associated with type 2 diabetes: a randomized clinical study
  99. Effect of Linagliptin on Cognitive Performance in Patients With Type 2 Diabetes and Cardiorenal Comorbidities: The CARMELINA Randomized Trial
  100. Effect of probiotic on serum cytokines and matrix metalloproteinases profiles during monoiodoacetate-induced osteoarthritis in rats
  101. Crosstalk between gut microbiota and antidiabetic drug action
  102. Linagliptin Effects on Heart Failure and Related Outcomes in Individuals With Type 2 Diabetes Mellitus at High Cardiovascular and Renal Risk in CARMELINA
  103. Neuropathic diabetic foot ulcers treated with cerium dioxide nanoparticles: A case report
  104. Effect of Linagliptin vs Placebo on Major Cardiovascular Events in Adults With Type 2 Diabetes and High Cardiovascular and Renal Risk
  105. Beneficial effects of probiotic combination with omega-3 fatty acids in NAFLD: a randomized clinical study
  106. Polyphenol Compounds Melanin Prevented Hepatic Inflammation in Rats with Experimental Obesity
  107. Obeticholic Acid: A New Era in the Treatment of Nonalcoholic Fatty Liver Disease
  108. Wpływ Z56822977 na biosyntezę serotoniny w mózgu szczurów z otyłością wywołaną przez podawanie glutaminianu sodu
  109. The correction of the metabolic parameters of msg-induced obesity in rats by 2-[4-(benzyloxy) phenoxy] acetic acid
  110. Probiotics and nutraceuticals as a new frontier in obesity prevention and management
  111. Effect of alive probiotic on insulin resistance in type 2 diabetes patients: Randomized clinical trial
  112. The role of nanotechnology in food safety
  113. Rationale, design, and baseline characteristics of the CArdiovascular safety and Renal Microvascular outcomE study with LINAgliptin (CARMELINA®): a randomized, double-blind, placebo-controlled clinical trial in patients with type 2 diabetes and high ca...
  114. A multi-strain probiotic reduces the fatty liver index, cytokines and aminotransferase levels in NAFLD patients: evidence from a randomized clinical trial
  115. Efficacy of Probiotics and Smectite in Rats with Non-Alcoholic Fatty Liver Disease
  116. Immunomodulatory effects of stem cells: Therapeutic option for neurodegenerative disorders
  117. Cerium dioxide nanoparticles possess anti-inflammatory properties in the conditions of the obesity-associated NAFLD in rats
  118. H 2 S causes contraction and relaxation of major arteries of the rabbit
  119. Effects of polyphenol compounds melanin on NAFLD/NASH prevention
  120. The Impact of Hyperglycemia on VEGF Secretion in Retinal Endothelial Cells
  121. Attenuation coefficient measurement as novel real time ultrasound alternative to CAP (fibroscan)
  122. Effect of a probiotic on fatty liver index and liver stiffness in NAFLD patients: randomized clinical trial
  123. Nanocrystalline cerium dioxide efficacy for prophylaxis of erosive and ulcerative lesions in the gastric mucosa of rats induced by stress
  124. Perspectives and challenges of antioxidant therapy for atrial fibrillation
  125. Clinical Trials Investigating Immune Checkpoint Inhibitors in Non-Small-Cell Lung Cancer
  126. Probiotics Supplemented with Omega-3 Fatty Acids are More Effective for Hepatic Steatosis Reduction in an Animal Model of Obesity
  127. The Role of Liver Biopsy to Assess Alcoholic Liver Disease
  128. Prevention of NAFLD development in rats with obesity via the improvement of pro/antioxidant state by cerium dioxide nanoparticles
  129. Comparative experimental investigation on the efficacy of mono- and multiprobiotic strains in non-alcoholic fatty liver disease prevention
  130. Caffeine and cardiovascular diseases: critical review of current research
  131. Probiotics in prevention and treatment of obesity: a critical view
  132. Pathophysiological role of host microbiota in the development of obesity
  133. Probiotics for experimental obesity prevention: focus on strain dependence and viability of composition
  134. Antioxidative effects of cerium dioxide nanoparticles ameliorate age-related male infertility: optimistic results in rats and the review of clinical clues for integrative concept of men health and fertility
  135. Diagnostic accuracy of acyl-ghrelin and it association with non-alcoholic fatty liver disease in type 2 diabetic patients
  136. P0968 : Are the type of probiotic strains and their amount equally effective for NAFLD prevention? Experimental comparative study
  137. Diagnosis of experimental stetohepatosis using ultrasound shear wave elastography
  138. The Role of Liver Biopsy to Assess Non-Alcoholic Fatty Liver Disease
  139. Multiprobiotic therapy from childhood prevents the development of nonalcoholic fatty liver disease in adult monosodium glutamate-induced obese rats
  140. P269 SHORT-TERM PERIODIC ADMINISTRATION OF MULTIPROBIOTIC FROM CHILDHOOD PREVENTS DEVELOPMENT OF NONALCOHOLIC FATTY LIVER DISEASE IN ADULT MONOSODIUM GLUTAMATE-INDUCED OBESE RATS
  141. Insulin resistance and liver steatosis in chronic hepatitis C infection genotype 3
  142. Short-term periodic consumption of multiprobiotic from childhood improves insulin sensitivity, prevents development of non-alcoholic fatty liver disease and adiposity in adult rats with glutamate-induced obesity
  143. Metabolic profile and morpho-functional state of the liver in rats with glutamate-induced obesity
  144. 1329 DIAGNOSTIC ACCURACY OF A NEW ELASTOGRAPHIC METHOD (SHEAR WAVE™ ELASTOGRAPHY IMAGING) IN THE NONINVASIVE ASSESSMENT OF NON-ALCOHOLIC STEATOSIS IN PATIENTS WITH TYPE 2 DIABETES
  145. 1267 PERFORMANCE OF NEW ULTRASOUND METHOD FOR ASSESSING LIVER STIFFNESS – SHEAR WAVE™ ELASTOGRAPHY IMAGING IN RATS WITH EXPERIMENTAL OBESITY